Illumina Inc (ILMN.O)
245.85USD
23 Apr 2018
$1.25 (+0.51%)
$244.60
$245.73
$246.98
$244.29
763,099
852,937
$256.64
$167.98
About
Overall
Beta: | 0.86 |
Market Cap(Mil.): | $35,893.97 |
Shares Outstanding(Mil.): | 146.75 |
Dividend: | -- |
Yield (%): | -- |
Financials
ILMN.O | Industry | Sector | |
---|---|---|---|
P/E (TTM): | 41.17 | 33.33 | 33.60 |
EPS (TTM): | 5.94 | -- | -- |
ROI: | 21.34 | 9.89 | 13.19 |
ROE: | 35.42 | 14.70 | 15.00 |
BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies
* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES
Loxo, Illumina to partner for diagnostic tool targeting cancer
Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.
UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer
April 10 Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.
Loxo and Illumina in partnership over diagnostic for cancer drug
Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.
Loxo and Illumina in partnership over diagnostic for cancer drug
April 10 Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.
BRIEF-Loxo Oncology And Illumina To Partner On Developing Pan Cancer Companion Diagnostics
* LOXO ONCOLOGY AND ILLUMINA TO PARTNER ON DEVELOPING NEXT-GENERATION SEQUENCING-BASED PAN-CANCER COMPANION DIAGNOSTICS
BRIEF-Illumina Says CEO Francis Desouza's FY 2017 Total Compensation Was $8.8 Mln VS $8.4 Mln In FY 2016
* ILLUMINA SAYS PRESIDENT AND CEO FRANCIS DESOUZA'S FY 2017 TOTAL COMPENSATION WAS $8.8 MLN VS $8.4 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2H17H6F] Further company coverage:
BRIEF-Illumina Q4 GAAP Earnings Per Share $0.46
* ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2017
BRIEF-Illumina Awarded $26.7 Mln In Patent Suit Against Ariosa Diagnostics
* ILLUMINA AWARDED $26.7M IN PATENT SUIT AGAINST ARIOSA DIAGNOSTICS, INC.
Illumina wins $26.7 million in patent fight with Roche unit Ariosa
Gene testing company Illumina on Thursday won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche Holdings AG, of using patented prenatal testing technology without authorization.
Competitors
Price | Chg | |
---|---|---|
Agilent Technologies Inc (A.N) | $68.07 | +0.52 |
Roche Holding Ltd. (ROG.S) | CHF217.60 | +1.95 |
Roche Holding Ltd. (RO.S) | CHF221.40 | +1.40 |
Pacific Biosciences of California (PACB.OQ) | $2.56 | -0.03 |
Qiagen NV (QGEN.N) | $32.78 | -0.03 |
Thermo Fisher Scientific Inc. (TMO.N) | $216.35 | +0.46 |